Nothing Special   »   [go: up one dir, main page]

LT3753937T - Atr inhibitor and application thereof - Google Patents

Atr inhibitor and application thereof

Info

Publication number
LT3753937T
LT3753937T LTEPPCT/CN2019/074578T LTCN2019074578T LT3753937T LT 3753937 T LT3753937 T LT 3753937T LT CN2019074578 T LTCN2019074578 T LT CN2019074578T LT 3753937 T LT3753937 T LT 3753937T
Authority
LT
Lithuania
Prior art keywords
application
atr inhibitor
atr
inhibitor
Prior art date
Application number
LTEPPCT/CN2019/074578T
Other languages
Lithuanian (lt)
Inventor
Wenyuan Qian
Jian Wang
Jie Li
Jian Li
Shuhui Chen
Original Assignee
Wuxi Biocity Biopharmaceutics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biocity Biopharmaceutics Co., Ltd. filed Critical Wuxi Biocity Biopharmaceutics Co., Ltd.
Publication of LT3753937T publication Critical patent/LT3753937T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
LTEPPCT/CN2019/074578T 2018-02-07 2019-02-02 Atr inhibitor and application thereof LT3753937T (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810124494 2018-02-07
CN201811361512 2018-11-15
PCT/CN2019/074578 WO2019154365A1 (en) 2018-02-07 2019-02-02 Atr inhibitor and application thereof

Publications (1)

Publication Number Publication Date
LT3753937T true LT3753937T (en) 2024-02-26

Family

ID=67548753

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/CN2019/074578T LT3753937T (en) 2018-02-07 2019-02-02 Atr inhibitor and application thereof

Country Status (20)

Country Link
US (1) US11434232B2 (en)
EP (1) EP3753937B1 (en)
JP (1) JP7290651B2 (en)
CN (1) CN111712499B (en)
AU (1) AU2019217388C1 (en)
BR (1) BR112020016020A8 (en)
CA (1) CA3090330A1 (en)
DK (1) DK3753937T3 (en)
ES (1) ES2970074T3 (en)
FI (1) FI3753937T3 (en)
HR (1) HRP20240161T1 (en)
HU (1) HUE065957T2 (en)
IL (1) IL276489B2 (en)
LT (1) LT3753937T (en)
PL (1) PL3753937T3 (en)
PT (1) PT3753937T (en)
RS (1) RS65147B1 (en)
SG (1) SG11202007485PA (en)
SI (1) SI3753937T1 (en)
WO (1) WO2019154365A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378799A1 (en) * 2019-06-06 2022-12-01 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-tri-substituted pyrimidine compound as atr kinase inhibitor
WO2021023272A1 (en) * 2019-08-06 2021-02-11 石家庄智康弘仁新药开发有限公司 Crystalline form of atr inhibitor and use thereof
US20230212160A1 (en) 2020-05-20 2023-07-06 Beijing Tide Pharmaceutical Co., Ltd. 2,4,6-tri-substituted pyrimidine compounds as atr kinase inhibitors
KR20230012586A (en) * 2020-05-29 2023-01-26 썬전 링팡 바이오테크 컴퍼니 리미티드 Fluoropyrrolopyridine-based compounds and uses thereof
EP4171650A1 (en) * 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atr inhibitor
MX2023000198A (en) * 2020-07-03 2023-02-22 Antengene Discovery Ltd Atr inhibitors and uses thereof.
CN116178366A (en) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 Crystal forms of fluoropyridine pyrrole compound and preparation method thereof
CN118510761A (en) * 2022-01-06 2024-08-16 上海德琪医药科技有限公司 Crystalline forms of ATR inhibitors
WO2023215133A1 (en) * 2022-05-02 2023-11-09 AcuraStem Incorporated Pikfyve kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
UY32351A (en) 2008-12-22 2010-07-30 Astrazeneca Ab PIRIMIDINIL INDOL COMPOUNDS FOR USE AS ATR INHIBITORS
SA111320519B1 (en) * 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl Compounds for Use as ATR Inhibitors
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
TWI656121B (en) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(morpholin-4-yl)-1,7-naphthyridine
EP3679041B1 (en) 2017-09-08 2022-07-06 Newave Pharmaceutical Inc. Substituted pyrrolopyridines as atr inhibitors

Also Published As

Publication number Publication date
PL3753937T3 (en) 2024-04-02
CA3090330A1 (en) 2019-08-15
DK3753937T3 (en) 2024-02-12
ES2970074T3 (en) 2024-05-24
RS65147B1 (en) 2024-02-29
FI3753937T3 (en) 2024-01-31
HUE065957T2 (en) 2024-07-28
IL276489B2 (en) 2024-09-01
AU2019217388C1 (en) 2024-03-07
EP3753937A4 (en) 2021-07-07
AU2019217388B2 (en) 2023-11-09
BR112020016020A8 (en) 2023-04-25
BR112020016020A2 (en) 2020-12-08
CN111712499B (en) 2023-06-02
JP2021512908A (en) 2021-05-20
AU2019217388A1 (en) 2020-09-03
SI3753937T1 (en) 2024-03-29
IL276489B1 (en) 2024-05-01
US20200399260A1 (en) 2020-12-24
HRP20240161T1 (en) 2024-04-12
WO2019154365A1 (en) 2019-08-15
JP7290651B2 (en) 2023-06-13
IL276489A (en) 2020-09-30
EP3753937B1 (en) 2024-01-10
SG11202007485PA (en) 2020-09-29
PT3753937T (en) 2024-02-06
RU2020128324A (en) 2022-03-09
CN111712499A (en) 2020-09-25
RU2020128324A3 (en) 2022-03-09
EP3753937A1 (en) 2020-12-23
US11434232B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
IL276489A (en) Atr inhibitor and application thereof
IL276095A (en) Gcn2 inhibitors and uses thereof
PT3626699T (en) Ssao inhibitor
IL276147A (en) Gcn2 inhibitors and uses thereof
IL277794A (en) Atf6 inhibitors and uses thereof
EP3587419A4 (en) Fgfr inhibitor and application thereof
ZA202002172B (en) Pde9 inhibitor and use thereof
EP3572400C0 (en) Ezh2 inhibitor and use thereof
PT3621694T (en) Lrrc33 inhibitors and use thereof
IL282350A (en) Rgmc-selective inhibitors and use thereof
SG10201913927VA (en) Kinase inhibitors and uses thereof
PT3712147T (en) Sglts inhibitor and application thereof
ZA202102192B (en) Fgfr4 inhibitor and use thereof
IL279276A (en) Erk inhibitor and use thereof
EP3786156C0 (en) 10h-phenothiazine ferroptosis inhibitor and preparation method therefor and application thereof
EP3463371A4 (en) Ku inhibitors and their use
IL283106A (en) Erk inhibitors and uses thereof
IL280408A (en) Cdk inhibitors and uses thereof
ZA202002825B (en) Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof
EP3892619A4 (en) SELECTIVE PI3Ko INHIBITOR AND USE THEREOF
GB201908884D0 (en) Inhibitors and use
GB201809939D0 (en) Eastase inhibitor